Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Determinants of government HIV/AIDS financing: a 10-year trend analysis from 125 low- and middle-income countries.

Ávila C, Loncar D, Amico P, De Lay P.

BMC Public Health. 2013 Jul 19;13:673. doi: 10.1186/1471-2458-13-673.

2.

Cost-effectiveness analysis of Option B+ for HIV prevention and treatment of mothers and children in Malawi.

Fasawe O, Avila C, Shaffer N, Schouten E, Chimbwandira F, Hoos D, Nakakeeto O, De Lay P.

PLoS One. 2013;8(3):e57778. doi: 10.1371/journal.pone.0057778. Epub 2013 Mar 12.

3.

Pattern and levels of spending allocated to HIV prevention programs in low- and middle-income countries.

Amico P, Gobet B, Avila-Figueroa C, Aran C, De Lay P.

BMC Public Health. 2012 Mar 21;12:221. doi: 10.1186/1471-2458-12-221.

4.

Writing on the wall for UNAIDS: UNAIDS replies.

De Lay P.

BMJ. 2008 May 31;336(7655):1206. doi: 10.1136/bmj.a160. No abstract available.

5.

Are we spending too much on HIV?

de Lay P, Greener R, Izazola JA.

BMJ. 2007 Feb 17;334(7589):345. No abstract available.

6.

Stool diagnosis of giardiasis using a commercially available enzyme immunoassay to detect Giardia-specific antigen 65 (GSA 65).

Rosoff JD, Sanders CA, Sonnad SS, De Lay PR, Hadley WK, Vincenzi FF, Yajko DM, O'Hanley PD.

J Clin Microbiol. 1989 Sep;27(9):1997-2002.

7.

Treating Southeast Asian patients.

Gilman S, De Lay PR.

West J Med. 1989 Mar;150(3):348. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk